# US 2008/0306258 A1 · Cyclopropane compounds and pharmaceutical use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306258 A1
- Document ID: US20080306258A1
- Status: Published application
- Kind: A1
- Application number: 12/149,683
- Filed: 2008-05-06
- Published: 2008-12-11
- Earliest claimed: 2003-12-15
- Assignees: Japan Tobacco Inc.
- Inventors: Takashi Inaba; Julia Haas; Makoto Shiozaki; Nicole M. Littmann; Katsutaka Yasue; Steven W. Andrews; Atushi Sakai; Andrew M. Fryer; Takafumi Matsuo; Ellen R. Laird; Akira Suma; Yuichi Shinozaki; Yoshikazu Hori; Hiroto Imai; Tamotsu Negoro
- Web page: https://patentgrep.com/patent/US20080306258A1

## CPC

- C07C 311/29: having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/18: for HIV
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 311/13: the carbon skeleton containing six-membered aromatic rings
- C07C 311/20: having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C 311/22: Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C 311/46: Y being a hydrogen or a carbon atom
- C07D 205/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 207/48: Sulfur atoms
- C07D 209/44: Iso-indoles; Hydrogenated iso-indoles
- C07D 211/58: attached in position 4
- C07D 211/96: Sulfur atom
- C07D 213/18: Salts thereof
- C07D 213/65: attached in position 3 or 5
- C07D 213/71: to which a second hetero atom is attached
- C07D 213/74: Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C07D 213/81: Amides; Imides
- C07D 213/82: in position 3
- C07D 217/08: with a hetero atom directly attached to the ring nitrogen atom
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 233/64: with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C07D 237/12: Halogen atoms or nitro radicals
- C07D 239/22: with hetero atoms directly attached to ring carbon atoms
- C07D 243/08: not condensed with other rings
- C07D 257/04: Five-membered rings
- C07D 261/08: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 271/06: 1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D 271/107: with two aryl or substituted aryl radicals attached in positions 2 and 5
- C07D 277/26: Radicals substituted by sulfur atoms
- C07D 277/36: Sulfur atoms
- C07D 277/82: Nitrogen atoms
- C07D 295/26: Sulfur atoms
- C07D 307/79: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D 307/91: Dibenzofurans; Hydrogenated dibenzofurans
- C07D 333/18: by sulfur atoms
- C07D 333/34: Sulfur atoms
- C07D 333/36: Nitrogen atoms
- C07D 333/38: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 333/62: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 513/04: Ortho-condensed systems
- C07C 2601/02: with a three-membered ring
- C07C 2601/14: The ring being saturated
- C07C 2603/08: containing three- or four-membered rings
- C07C 2603/18: Fluorenes; Hydrogenated fluorenes
- C07C 2603/30: containing seven-membered rings
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a cyclopropane compound of formula (1): wherein R1 is —(CH2)m—X—(CH2)n-A1 etc., wherein m and n are the same or different and each is 0 to 6, X is a single bond, etc. and A1 is a substituted C3-14 hydrocarbon ring group, etc.; R2 and R3 are the same or different and each is a hydrogen atom, —(CH2)p—X1—(CH2)q-A2, etc., wherein p and q are the same or different and each is 0 to 6, X1 is a single bond, etc. and A2 is an optionally substituted C3-14 hydrocarbon ring group, etc.; R4 is —CO2R9, etc., wherein R9 is a hydrogen atom, etc.; and R20 and R21 are the same or different and each is a hydrogen atom, —(CH2)m12—X12—(CH2)m12—R30 etc., wherein m12 and m12 are the same or different and each is 0 to 6, X12 is a single bond, etc. and R30 is a hydrogen atom, etc.; or a prodrug thereof or a pharmaceutically acceptable salt thereof.

## Claims

### Claim 1

A cyclopropane compound of formula (1):
wherein
R1 is selected from
(1) a substituted C1-6 alkyl group
and
(2) —(CH2)m—X—(CH2)n-A1,
wherein
m and n are the same or different and each is selected from 0 and an integer ranging from 1 to 6,
X is a linker selected from the following group A,
group A:
(a) a single bond,
(b) a C1-6 alkylene group,
(c) a C2-6 alkenylene group,
(d) a C2-6 alkynylene group,
(e) —O—,
(f) —N(R5)—,
(g) —S(O)m1—,
(h) —CO—,
(i) —COO—,
(j) —OCO—,
(k) —CON(R5)—,
(l) —N(R5)CO—,
(m) —SO2N(R5)—,
(n) —N(R5)SO2—,
(o) —N(R5)CON(R6)—,
(p) —N(R5)SO2N(R6)—,
(q) —OCON(R5)—,
(r) —N(R5)COO—,
and
(s) —S(O)m1—(CH2)n1—CO—;
wherein
R5 and R6 are the same or different and each is selected from a hydrogen atom, a C1-6 alkyl group optionally substituted by halogen atoms or hydroxyl groups, a C3-14 hydrocarbon ring group and a heterocyclic group,
m1 is selected from 0 and an integer ranging from 1 to 2 and
n1 is selected from an integer ranging from 1 to 2, and
A1 is selected from a substituted C3-14 hydrocarbon ring group and a substituted heterocyclic group;
R2 and R3 are the same or different and each is selected from
(1) —(CH2)p—X1—(CH2)q-A2,
wherein
p and q are the same or different and each is selected from 0 and an integer ranging from 1 to 6,
X1 is a linker selected from the above-mentioned group A and
A2 is selected from an optionally substituted C3-14 hydrocarbon ring group and an optionally substituted heterocyclic group,
and
(2) —(CH2)m8—X8—(CH2)n8—R27,
wherein
m8 and n8 are the same or different and each is selected from 0 and an integer ranging from 1 to 6,
X8 is a linker selected from the above-mentioned group A and
R27 is a substituent selected from the following group B,
group B:
(a) a hydrogen atom,
(b) a halogen atom,
(c) a hydroxyl group,
(d) a nitro group,
(e) a cyano group,
(f) a carboxyl group,
(g) an amino group,
(h) an amido group,
(i) a C2-6 acyl group,
(j) a halogenated C1-6 alkyl group,
(k) a C1-6 alkyl group optionally substituted by hydroxyl groups,
(l) a C2-6 alkenyl group optionally substituted by halogen atoms,
(m) a C2-6 alkynyl group,
(n) a C1-6 alkoxy group optionally substituted by hydroxyl groups,
(o) a C1-6 alkoxy-C1-6 alkyl group,
(p) a C1-6 alkoxy-carbonyl group,
(q) a C1-6 alkyl-aminocarbonyl group optionally substituted by halogen atoms,
(r) a mono(C1-6 alkyl)amino group,
(s) a di(C1-6 alkyl)amino group,
(t) a C1-6 alkyl-carbonylamino group optionally substituted by halogen atoms,
(u) a C1-6 alkylsulfonyl group,
and
(v) a C1-6 alkylsulfonylamino group;
or A2 and R27 may be taken together to form an optionally substituted fused ring group,
or R2 and R3 may be taken together with a carbon atom bonded thereto to form the following ring
wherein m13 is selected from an integer ranging from 1 to 6,
provided that R2 and R3 are not hydrogen atoms at the same time;
R4 is selected from
(1) —CO2R9,
(2) —C(O)NHOR9,
(3) —C(O)NH—SO2—R9,
(4) —C(O)NHR9,
(5) —SH,
(6) —CH2CO2R9,
(7) —C(O)R9,
(8) —N(OH)COR9,
(9) —SN2H2R9,
(10) —SONHR9,
(11) —CH2CO2H,
(12) —PO(OH)2,
(13) —PO(OH)NHR9,
(14) —CH2SH,
(15) —CH2OH,
(16) —(CH2)r1—PO(OH)—(CH2)r2—R9,
(17) —NHR9,
(18) —NH—NHR9,
and
(19) —(CH2)r1—R50;
wherein
r1 and r2 are the same or different and each is selected from 0 and an integer ranging from 1 to 6,
R9 is selected from
(1) a hydrogen atom,
(2) an optionally substituted C1-10 alkyl group,
(3) an optionally substituted C6-14 aryl-C1-6 alkyl groups
and
(4) —(CH2)m9—X9—(CH2)n9—R28;
wherein
m9 and n9 are the same or different and each is selected from 0 and an integer ranging from 1 to 6,
X9 is a linker selected from the above-mentioned group A and
R28 is a substituent selected from the following group C,
group C:
(a) a hydrogen atom,
(b) a halogen atom,
(c) a hydroxyl group,
(d) a nitro group,
(e) a cyano group,
(f) a carboxyl group,
(g) an amino group,
(h) an amido group,
(i) a C2-6 acyl group,
(j) a halogenated C1-6 alkyl group,
(k) a C1-6 alkyl group optionally substituted by hydroxyl groups,
(l) a C2-6 alkenyl group optionally substituted by halogen atoms,
(m) a C2-6 alkynyl group,
(n) a C1-6 alkoxy group optionally substituted by hydroxyl groups,
(o) a C1-6 alkoxy-C1-6 alkyl group,
(p) a C1-6 alkoxy-carbonyl group,
(q) a C1-6 alkyl-aminocarbonyl group optionally substituted by halogen atoms,
(r) a mono(C1-6 alkyl)amino group,
(s) a di(C1-6 alkyl)amino group,
(t) a C1-6 alkyl-carbonylamino group optionally substituted by halogen atoms,
(u) a C1-6 alkylsulfonyl group,
(v) a C1-6 alkylsulfonylamino group,
(w) a C3-14 hydrocarbon ring group optionally substituted by 1 to 5 substituent(s) selected from the above-mentioned group B, and
(x) a heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above-mentioned group B,
and
R50 is selected from an optionally substituted C3-14 hydrocarbon ring group and an optionally substituted heterocyclic group;
or R9 of —C(O)NHR9, A2 and the cyclopropane ring may be taken together to form an optionally further substituted fused ring;
R20 and R21 are the same or different and each is selected from
(1) —(CH2)m10—X10—(CH2)n10-A3,
wherein
m10 and n10 are the same or different and each is selected from 0 and an integer ranging from 1 to 6,
X10 is a linker selected from the above-mentioned group A
and
A3 is selected from an optionally substituted C3-14 hydrocarbon ring group and an optionally substituted heterocyclic group,
and
(2) —(CH2)m12—X12—(CH2)n12—R30,
wherein
m12 and n12 are the same or different and each is selected from 0 and an integer ranging from 1 to 6,
X12 is a linker selected from the above-mentioned group A
and
R30 is a substituent selected from the above-mentioned group B;
or A2, R30 and the cyclopropane ring may be taken together to form a optionally further substituted fused ring,
or R9 of —CO2R9, R20 and the cyclopropane ring may be taken together to form an optionally further substituted fused ring,
or R20 and R21 may be taken together with a carbon atom bonded thereto to form the following ring
wherein m14 is selected from an integer ranging from 1 to 6;
or a pharmaceutically acceptable salt thereof.

### Claim at position 2

2-34. (canceled)
